- MGC Pharma (MXC) recruits its first patient for the phase three CimetrA clinical trial in Israel
- MXC is testing the treatment’s safety and efficacy on patients with moderate forms of COVID-19
- A total of 252 patients will take place in the trial which will provide additional data for CimetrA’s Investigational Medicinal Product (IMP) status
- MXC says the data from the trial should meet the European Medical Agency’s qualification as well
- Company shares are trading up 5.26 per cent at 4 cents each
MGC Pharma (MXC) has recruited its first patient for the phase three CimetrA clinical trial at the Rambam Medical Centre in Israel.
The trial will test the treatment’s safety and efficacy on hospitalised patients with moderate forms of COVID-19.
It’ll also test how the treatment works when combined with a new drug carrier, which should deliver natural ingredients more effectively in higher concentrations.
A total of 252 patients will take place in the study in Israel and the additional data from the trial will be used to advance CimetrA’s Investigational Medicinal Product (IMP) status.
The treatment has already completed IMP production, validation, and ethics committee approval and MXC wants the data from this trial to meet the European Medicines Agency’s (EMA) qualification.
Explaining the significance of the first patient, MGC Pharma co-founder and Managing Director Roby Zomer said it meant the trial could now commence.
Mr Zomer added the company was excited to get a better understanding of the valid claims that can be made for CimetrA.
“The commencement of the phase three clinical trial is a milestone achievement for both MGC Pharma and the medicinal cannabis industry,” Mr Zomer said.
“Testing CimetrATM as an IMP will have great implications for those suffering with COVID-19 and ensure the risk of healthcare systems becoming overwhelmed is minimised.”
MGC Pharma shares were trading up 5.26 per cent at 4 cents each towards the close of market on Tuesday.